search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


The Compass Trial.


- candidate number14128
- NTR NumberNTR3764
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR21-dec-2012
- Secondary IDsNL42723.058.12 CCMO
- Public TitleThe Compass Trial.
- Scientific TitleA randomized trial to increase the efficiency of the prevention of contrast induced acute kidney injury. The Compass trial.
- ACRONYM
- hypothesisCI-AKI preventive hydration is not needed in patients with a creatinine clearence between 30-60 ml/min undergoing intravenous contrast media-enhanced CT.
- Healt Condition(s) or Problem(s) studiedContrast induced acute kidney injury (CI-AKI)
- Inclusion criteria1. Patients with an eGFR (estimated glomerular filtration rate 30-45 ml/min);
2. Patients with an eGFR 45-60 ml/min and diabetes mellitus (either type 1 or 2);
3. Patients with an eGFR 45-60 ml/min and at least two of the following: Peripheral artery disease, congestive heart failure, age > 75 years, anemia, contrastvolumes > 150 cc or the use of nephrotoxic medication;
4. Informed consent.
- Exclusion criteria1. eGFR < 30 ml/min;
2. Age < 18 years;
3. Patients with other intravenous contrast administrations (including intravenous contrast enhanced MRI) < 7 days of study CT-scan OR in 5 days following study CT-scan;
4. Pregnancy;
5. Renal transplantation in the last 3 years;
6. Previous participation to the Compass trial;
7. Dehydrated patients (systolic blood pressure < 100 mmHg);
8. Proven instable renal function in the four weeks prior to randomisation (increase or decrease in serum creatinine > 20%);
9. Known allergy for iodinated contrast media.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingNone
- controlPlacebo
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-feb-2013
- planned closingdate1-aug-2015
- Target number of participants575
- InterventionsRandomisation in a 1:1 ratio to:
1. 1 hour prehydration with 250 ml 1.4% sodium bicarbonate;
2. No preventive hydration.
- Primary outcomeMean relative increase in serum creatinine.
- Secondary outcome1. Incidence of CIN;
2. Recovery of renal function 2 months after CT in patients who developed CIN;
3. Mean relative increase in serum creatinine 7-14 days after contrast administration;
4. Acute kidney injury according to the serum creatinine based RIFLE criteria;
5. The need for dialysis;
6. (Re)hospitalisation, duration of hospitalisation in the two months following randomisation;
7. Visits to the outpatient clinic in the two months following randomisation.
- TimepointsBaseline, 2-4 days, 7-14 days, and 2 months post CT.
- Trial web siteN/A
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIES Judith Kooiman
- CONTACT for SCIENTIFIC QUERIES Judith Kooiman
- Sponsor/Initiator Leiden University Medical Center (LUMC)
- Funding
(Source(s) of Monetary or Material Support)
Leiden University Medical Center (LUMC)
- PublicationsN/A
- Brief summaryContrast induced nephropathy (CIN), an acute decline in renal function, may occur following intravenous iodinated contrast media-enhanced CT. In the majority of patients, CIN is a reversible condition with full recovery of renal function within two months. The CBO guideline recommends preventive hydration in patients at high risk for the development of CIN (high risk defined as estimated kidney function (eGFR) <45 mL / min OR eGFR 45-60 ml / min in combination with comorbidities also at risk of CIN). The standard preventive treatment recommeded by the CBO guideline consists of intravenous hydration with 1000 ml 0.9% of saline infused within 3-12 hours prior to and after contrast administration is. The implementation of the CBO guideline in clinical practice is expensive due to the hospitalisation that is needed for preventive hydration (yearly cost in the Netherlands : 25.9-39.0 million). Previously, a randomized trial was conducted which showed that one-hour prehydration with sodium bicarbonate is non-inferior to pre-and posthydration with saline in patients with chronic kidney disease undergoing intravenous contrast media-enhanced CT. The use of sodium bicarbonate pre-hydration stronlgy reduced health care costs (by 66%) associated with preventive hydration, as it does not require hospitalisation but could place in daycare or even an outpatient setting.

The risk of CIN or irreversible kidney damage is very limited, especially in the group of patients with moderate renal impairment (estimated renal clearance 30-60 ml / min). However, this patient group forms the majority of patients with an indication for CIN preventive hydration. A recently published meta-analysis showed renal function to be reduced at two months post CT in only 1.1% of patients, and 0.06% of patients undergoing CT had a (temporarily) need for dialysis. Other studies showed a risk of CIN of 0-2% in patients with moderate renal impairment when preventive hydration is applied. Therefore, preventive hydration might not even be necessary in patients with moderate renal impairment. Reducting eGFR cut-off levels for preventive hydration to an eGFR <30 ml /min could result in about 70% extra savings in healthcare costs for preventive hydration.

Objective of the study:
To study whether the existing eGFR cut-off levels for preventive hydration of < 45 ml/min or between 45-60 ml/min in combination of other comorbidity at risk of CIN can be safely lowered to an eGFR < 30 ml/min, regarsless of the presence of other risk factors for the development of CIN.

Study design:
Open label, non-inferiority randomized trial.
- Main changes (audit trail)
- RECORD21-dec-2012 - 11-apr-2013


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl